

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES  
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

## 144: Filer Information

Filer CIK 0001157524  
Filer CCC XXXXXXXXX  
Is this a LIVE or TEST Filing?  LIVE  TEST

### Submission Contact Information

Name  
Phone  
E-Mail Address

## 144: Issuer Information

Name of Issuer Verona Pharma plc  
SEC File Number 001-38067  
Address of Issuer 3 More London Riverside  
LONDON  
UNITED KINGDOM  
SE1 2RE  
Phone 981489389  
Name of Person for Whose Account the Securities are To Be Sold The Biotech Growth Trust PLC

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Shareholder

## 144: Securities Information

Title of the Class of Securities To Be Sold American Depository Shares  
Themis Trading LLC  
10 Town Square, Suite 100  
Name and Address of the Broker Chatham  
NJ  
07928  
Number of Shares or Other Units To Be Sold 311598  
Aggregate Market Value 6403338.90  
Number of Shares or Other Units Outstanding 75622575  
Approximate Date of Sale 03/09/2023  
Name the Securities Exchange Nasdaq Stock Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

## 144: Securities To Be Sold

Title of the Class American Depository Shares  
Date you Acquired 07/17/2020  
Nature of Acquisition Transaction public offering  
Name of Person from Whom Acquired Issuer  
Is this a Gift?  Checkbox not checked Date Donor Acquired

Amount of Securities Acquired 666667  
Date of Payment 07/17/2020  
Nature of Payment Cash

If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144: Securities Sold During The Past 3 Months

Name and Address of Seller The Biotech Growth Trust PLC  
c/o OrbiMed Capital LLC  
601 Lexington Avenue, 54th Floor  
New York  
NY  
10022  
Title of Securities Sold American Depository Shares  
Date of Sale 12/22/2022  
Amount of Securities Sold 229556  
Gross Proceeds 4997434.12

## 144: Remarks and Signature

Remarks Additional sales in the last three months by The Biotech Growth Trust PLC (c/o OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor, New York, NY 10022) of American Depository Shares on 12/23/2022. 125,513 American Depository Shares were sold for gross proceeds of \$2,866,716.92. OrbiMed Capital LLC is the portfolio manager of The Biotech Growth Trust PLC.

Date of Notice 03/09/2023

### ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ Douglas Coon, Chief Compliance Officer, OrbiMed Capital LLC, portfolio manager for The Biotech Growth Trust PLC

**ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)**